Antibody engineering

Mabswitch Inc., (Mabswitch) today announced that it has received a second Small Business Innovation Research (SBIR) Phase I award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to advance its remote-controlled Peptide-Centric CAR (PC-CAR) T-cell therapy program for hard-to-treat solid tumors. The program will be conducted in collaboration with Dr. Mark Yarmarkovich and his research group at New York University (NYU).